Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,250,176

« Back to Dashboard

Which drugs does patent 7,250,176 protect, and when does it expire?


Patent 7,250,176 protects AUGMENTIN XR and is included in one NDA. There has been one Paragraph IV challenge on Augmentin XR.

This patent has ninety-two patent family members in forty-seven countries.

Summary for Patent: 7,250,176

Title:Method of treating a bacterial infection
Abstract:Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
Inventor(s): Storm; Kevin H. (Bristol, TN), Conley; Creighton P. (Bristol, TN), Roush; John A. (Kingsport, TN)
Assignee: Beecham Pharmaceuticals (Pte) Limited (Jurong, SG)
Application Number:09/689,483
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Dr Reddys Labs Inc
AUGMENTIN XR
amoxicillin; clavulanate potassium
TABLET, EXTENDED RELEASE;ORAL050785-001Sep 25, 2002ABRXYesYes7,250,176► Subscribe MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,250,176

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,746,692 Modified release pharmaceutical formulation comprising amoxycillin► Subscribe
6,783,773 Composition comprising amoxicillin and potassium clavulanate► Subscribe
6,878,386 Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate► Subscribe
6,294,199 Method of treating a bacterial infection comprising administering amoxycillin► Subscribe
7,217,430Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,250,176

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Bulgaria65006► Subscribe
Brazil0009718► Subscribe
Brazil0009719► Subscribe
Canada2366304► Subscribe
Canada2369684► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot